Amicus Therapeutics (FOLD) Competitors $6.09 -0.21 (-3.33%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.24 +0.15 (+2.45%) As of 07/11/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. RGEN, MDGL, HALO, IONS, ALKS, LGND, BCRX, CLDX, INVA, and DVAXShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Its Competitors Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Celldex Therapeutics Innoviva Dynavax Technologies Repligen (NASDAQ:RGEN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations. Do institutionals & insiders have more ownership in RGEN or FOLD? 97.6% of Repligen shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is RGEN or FOLD more profitable? Repligen has a net margin of -3.93% compared to Amicus Therapeutics' net margin of -5.41%. Amicus Therapeutics' return on equity of 4.67% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Repligen-3.93% 4.53% 3.17% Amicus Therapeutics -5.41%4.67%1.05% Do analysts rate RGEN or FOLD? Repligen currently has a consensus price target of $170.75, indicating a potential upside of 31.15%. Amicus Therapeutics has a consensus price target of $16.22, indicating a potential upside of 166.37%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69Amicus Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has more volatility and risk, RGEN or FOLD? Repligen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Which has better valuation & earnings, RGEN or FOLD? Repligen has higher revenue and earnings than Amicus Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$634.44M11.53-$25.51M-$0.45-289.31Amicus Therapeutics$528.29M3.55-$56.11M-$0.09-67.67 Does the media favor RGEN or FOLD? In the previous week, Amicus Therapeutics had 6 more articles in the media than Repligen. MarketBeat recorded 14 mentions for Amicus Therapeutics and 8 mentions for Repligen. Repligen's average media sentiment score of 0.97 beat Amicus Therapeutics' score of 0.83 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRepligen beats Amicus Therapeutics on 9 of the 16 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.88B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-67.6620.8528.2620.26Price / Sales3.55303.05437.10166.10Price / CashN/A42.1137.1257.67Price / Book9.377.638.045.49Net Income-$56.11M-$55.05M$3.19B$250.45M7 Day Performance-1.06%8.43%3.62%4.79%1 Month Performance1.00%8.14%5.98%9.59%1 Year Performance-41.50%1.62%29.39%16.41% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.1348 of 5 stars$6.09-3.3%$16.22+166.4%-41.5%$1.88B$528.29M-67.66480News CoverageAnalyst RevisionRGENRepligen4.6023 of 5 stars$124.38+0.7%$172.83+39.0%+3.4%$6.99B$634.44M-276.401,778Positive NewsAnalyst ForecastMDGLMadrigal Pharmaceuticals4.2586 of 5 stars$302.64+0.6%$420.63+39.0%+10.4%$6.72B$317.38M-16.7790News CoveragePositive NewsHALOHalozyme Therapeutics4.8246 of 5 stars$52.02-0.4%$61.90+19.0%+7.5%$6.41B$1.02B13.84390News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeIONSIonis Pharmaceuticals4.6042 of 5 stars$39.51-0.7%$57.88+46.5%-13.1%$6.29B$705M-13.211,069Positive NewsALKSAlkermes4.7999 of 5 stars$28.61-0.7%$40.00+39.8%+28.5%$4.72B$1.56B13.691,800Positive NewsLGNDLigand Pharmaceuticals4.0777 of 5 stars$113.68-0.4%$146.14+28.6%+22.4%$2.19B$167.13M-15.9780News CoverageInsider TradeBCRXBioCryst Pharmaceuticals4.2116 of 5 stars$8.96-4.3%$16.89+88.5%+22.5%$1.87B$450.71M-34.46530CLDXCelldex Therapeutics2.494 of 5 stars$20.35+0.3%$50.11+146.2%-42.4%$1.35B$7.02M-7.54150Positive NewsINVAInnoviva4.1109 of 5 stars$20.09+0.7%$55.00+173.8%+12.2%$1.26B$358.71M-19.89100News CoverageAnalyst ForecastAnalyst RevisionDVAXDynavax Technologies4.3726 of 5 stars$9.92+0.1%$24.00+141.9%-1.6%$1.19B$277.25M-19.08350News Coverage Related Companies and Tools Related Companies RGEN Alternatives MDGL Alternatives HALO Alternatives IONS Alternatives ALKS Alternatives LGND Alternatives BCRX Alternatives CLDX Alternatives INVA Alternatives DVAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
